Mast Therapeutics (NYSE: MSTX) today announced that data from nonclinical studies investigating vepoloxamer, its lead product candidate, will be featured ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE